Study |
Time |
Treatment group |
Outcome (scale) |
N of Pts |
Baseline Mean |
End of Study Mean |
Absolute Benefit |
Relative Difference |
Scale 1994a |
5‐13 wk |
E: Hylan G‐F 20 |
Weight bearing pain (0‐100 mm VAS) |
25 |
61 |
27 |
‐20 (I) |
‐29.9% (I) |
|
|
C: Saline |
|
25 |
67 |
53 |
|
|
Scale 1994a |
5‐13 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
25 |
29 |
16 |
‐13 (I) |
‐50.0% (I) |
|
|
C: Saline |
|
25 |
26 |
26 |
|
|
Scale 1994b |
5‐13 wk |
E: Hylan G‐F 20 |
Weight bearing pain (0‐100 mm VAS) |
15 |
65 |
11 |
‐27 (I) |
‐38.6% (I) |
|
|
C: Saline |
|
15 |
70 |
43 |
|
|
Scale 1994b |
5‐13 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
15 |
30 |
2 |
‐10 (I) |
‐30.3% (I) |
|
|
C: Saline |
|
15 |
33 |
15 |
|
|
Wobig 1998 |
5‐13 wk |
E: Hylan G‐F 20 |
Weight bearing pain (0‐100 mm VAS) |
57 |
70 |
23 |
‐32 (I) |
‐42.7% (I) |
|
|
C: Saline |
|
60 |
75 |
60 |
|
|
Wobig 1998 |
5‐13 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
57 |
41 |
12 |
‐13 (I) |
‐28.3% (I) |
|
|
C: Saline |
|
60 |
46 |
30 |
|
|
Wobig 1999 |
5‐13 wk |
E: Hylan G‐F 20 |
Weight bearing pain (0‐100 mm VAS) |
38 |
70 |
32 |
‐1 (I) |
‐1.3% (I) |
|
|
C: Nonelastoviscous Hylan G‐F 20 |
|
36 |
80 |
43 |
|
|
Wobig 1999 |
5‐13 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
38 |
26 |
13 |
2 (W) |
7.4% (W) |
|
|
C: Nonelastoviscous Hylan G‐F 20 |
|
36 |
27 |
12 |
|
|
Moreland 1993 |
1‐4 wk |
E: Hylan GF 20 |
Pain on motion (0‐100 mm VAS) |
46 |
69 |
47 |
‐3 (I) |
‐4.3% (I) |
|
|
C: Arthrocentesis |
|
48 |
70 |
51 |
|
|
Moreland 1993 |
1‐4 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
46 |
60 |
36 |
6 (W) |
8% (W) |
|
|
C: Arthrocentesis |
|
48 |
75 |
45 |
|
|
Moreland 1993 |
1‐4 wk |
E: Hylan GF 20 |
Pain at rest (0‐100 mm VAS) |
46 |
61 |
39 |
‐2 (I) |
‐3.1% (I) |
|
|
C: Arthrocentesis |
|
48 |
64 |
44 |
|
|
Moreland 1993 |
1‐4 wk |
E: Hylan G‐F 20 |
Pain walking (0‐100 mm VAS) |
46 |
79 |
57 |
‐2 (I) |
‐2.5% (I) |
|
|
C: Arthrocentesis |
|
48 |
80 |
60 |
|
|
Moreland 1993 |
1‐4 wk |
E: Hylan GF 20 |
Pain overall (0‐100 mm VAS) |
46 |
78 |
55 |
‐2 (I) |
‐2.6% (I) |
|
|
C: Arthrocentesis |
|
48 |
78 |
57 |
|
|
Dickson 2001 |
5‐13 wk |
E: Hylan G‐F 20 |
WOMAC pain (0‐100 mm VAS) |
53 |
59 |
26 |
‐9 (I) |
‐15.5% (I) |
|
|
C: Arthrocentesis + Placebo capsules |
|
57 |
58 |
34 |
|
|
Dickson 2001 |
5‐13 wk |
E: Hylan G‐F 20 |
WOMAC function (0‐100 VAS) |
53 |
54 |
38 |
‐7 (I) |
‐12.5% (I) |
|
|
C: Arthrocentesis + Placebo capsules |
|
57 |
56 |
47 |
|
|
Dickson 2001 |
5‐13 wk |
E: Hylan G‐F 20 |
Lequesne Index (0‐24) |
53 |
13.9 |
10.9 |
‐1 (I) |
‐6.9% (I) |
|
|
C: Arthrocentesis + Placebo capsules |
|
57 |
14.5 |
12.5 |
|
|
Karlsson 2002b |
1‐4 wk |
E: Hylan G‐F 20 |
Pain on weight bearing (0‐100 mm VAS) |
88 |
63 |
45 |
3.0 (W) |
4.6% (W) |
|
|
C: Saline |
|
66 |
65 |
44 |
|
|
Karlsson 2002b |
5‐13 wk |
E: Hylan G‐F 20 |
Pain on weight bearing (0‐100 mm VAS) |
88 |
63 |
41 |
‐3.0 (I) |
‐4.6% (I) |
|
|
C: Saline |
|
66 |
65 |
46 |
|
|
Karlsson 2002b |
14‐26 wk |
E: Hylan G‐F 20 |
Pain on weight bearing (0‐100 mm VAS) |
88 |
63 |
43 |
1.0 (W) |
1.5% (W) |
|
|
C: Saline |
|
66 |
65 |
44 |
|
|
Karlsson 2002b |
5‐13 wk |
E: Hylan G‐F 20 |
WOMAC (0‐100 mm VAS) |
88 |
48.7 |
31.7 |
1.2 (W) |
2.5% (W) |
|
|
C: Saline |
|
66 |
48.9 |
30.7 |
|
|
Karlsson 2002b |
14‐26 wk |
E: Hylan G‐F 20 |
WOMAC (0‐100 mm VAS) |
88 |
48.7 |
31.9 |
‐1.0 (I) |
‐2.0% (I) |
|
|
C: Saline |
|
66 |
48.9 |
33.1 |
|
|
Karlsson 2002b |
14‐26 wk |
E: Hylan G‐F 20 |
Lequesne Index (0‐24) |
88 |
13.4 |
9.0 |
0.3 (W) |
2.2% (W) |
|
|
C: Saline |
|
66 |
13.6 |
8.9 |
|
|
Scale 1994a |
14‐26 wk |
E: Hylan G‐F 20 |
Pain on weight bearing (0‐100 mm VAS) |
15 |
61 |
18 |
‐33 (I) |
‐49.3 (I) |
|
|
C: Saline |
|
21 |
67 |
57 |
|
|
Scale 1994a |
14‐26 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
15 |
29 |
10 |
‐25 (I) |
‐96.2 (I) |
|
|
C: Saline |
|
21 |
26 |
32 |
|
|
Scale 1994b |
14‐26 wk |
E: Hylan G‐F 20 |
Pain on weight bearing (0‐100 mm VAS) |
15 |
65 |
22 |
‐18 (I) |
‐25.7 (I) |
|
|
C: Saline |
|
15 |
70 |
45 |
|
|
Scale 1994b |
14‐26 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
15 |
30 |
3 |
‐10 (I) |
‐30.3 (I) |
|
|
C: Saline |
|
15 |
33 |
16 |
|
|
Wobig 1998 |
14‐26 wk |
E: Hylan G‐F 20 |
Pain on weight bearing (0‐100 mm VAS) |
56 |
70 |
35 |
‐16 (I) |
‐21.3 (I) |
|
|
C: Saline |
|
60 |
75 |
56 |
|
|
Wobig 1998 |
14‐26 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
56 |
41 |
16 |
‐13 (I) |
‐28.3% (I) |
|
|
C: Saline |
|
60 |
46 |
34 |
|
|
Scale 1994a |
1‐4 wk |
E: Hylan G‐F 20 |
Weight bearing pain (0‐100 mm VAS) |
25 |
61 |
32 |
‐9 (I) |
‐13.4% (I) |
|
|
C: Saline |
|
25 |
67 |
47 |
|
|
Scale 1994a |
1‐4 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
25 |
29 |
18 |
‐8 (I) |
‐30.8% (I) |
|
|
C: Saline |
|
25 |
26 |
23 |
|
|
Scale 1994b |
1‐4 wk |
E: Hylan G‐F 20 |
Weight bearing pain (0‐100 mm VAS) |
15 |
65 |
22 |
‐17 (I) |
‐24.3% (I) |
|
|
C: Saline |
|
15 |
70 |
44 |
|
|
Scale 1994b |
1‐4 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
15 |
30 |
7 |
‐7 (I) |
‐21.2% (I) |
|
|
C: Saline |
|
15 |
33 |
17 |
|
|
Wobig 1998 |
1‐4 wk |
E: Hylan G‐F 20 |
Weight bearing pain (0‐100 mm VAS) |
57 |
70 |
31 |
‐17 (I) |
‐22.7% (I) |
|
|
C: Saline |
|
60 |
75 |
53 |
|
|
Wobig 1998 |
1‐4 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
57 |
41 |
15 |
‐6 (I) |
‐13.0% (I) |
|
|
C: Saline |
|
60 |
46 |
26 |
|
|
Wobig 1999 |
1‐4 wk |
E: Hylan G‐F 20 |
Weight bearing pain (0‐100 mm VAS) |
38 |
70 |
40 |
‐3 (I) |
‐3.8% (I) |
|
|
C: Saline |
|
36 |
80 |
53 |
|
|
Wobig 1998 |
1‐4 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
38 |
26 |
12 |
1 (W) |
3.7% (W) |
|
|
C: Saline |
|
36 |
27 |
12 |
|
|
Cubukcu 2004 |
1‐4 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
20 |
45 |
27 |
|
|
|
|
C: Saline |
|
10 |
54 |
37 |
|
|
Cubukcu 2004 |
5‐13 wk |
E: Hylan G‐F 20 |
Pain at night (0‐100 mm VAS) |
20 |
45 |
23 |
|
|
|
|
C: Saline |
|
10 |
54 |
44 |
|
|
Cubukcu 2004 |
1‐4 wk |
E: Hylan G‐F 20 |
Pain at rest (0‐100 mm VAS) |
20 |
47 |
29 |
|
|
|
|
C: Saline |
|
10 |
51 |
39 |
|
|
Cubukcu 2004 |
5‐13 wk |
E: Hylan G‐F 20 |
Pain at rest (0‐100 mm VAS) |
20 |
47 |
22 |
|
|
|
|
C: Saline |
|
10 |
51 |
41 |
|
|
Cubukcu 2004 |
1‐4 wk |
E: Hylan G‐F 20 |
Pain walking (0‐100 mm VAS) |
20 |
71 |
47 |
|
|
|
|
C: Saline |
|
10 |
67 |
51 |
|
|
Cubukcu 2004 |
5‐13 wk |
E: Hylan G‐F 20 |
Pain walking (0‐100 mm VAS) |
20 |
71 |
40 |
|
|
|
|
C: Saline |
|
10 |
67 |
54 |
|
|
Cubukcu 2004 |
1‐4 wk |
E: Hylan G‐F 20 |
Need for paracetamol (pill count) |
20 |
1.0 |
0.0 |
|
|
|
|
C: Saline |
|
10 |
0.9 |
0.1 |
|
|
Cubukcu 2004 |
5‐13 wk |
E: Hylan G‐F 20 |
Need for paracetamol (pill count) |
20 |
1.0 |
0.0 |
|
|
|
|
C: Saline |
|
10 |
0.9 |
0.7 |
|
|
Cubukcu 2004 |
1‐4 wk |
E: Hylan G‐F 20 |
WOMAC pain (5‐25) |
20 |
16 |
11 |
|
|
|
|
C: Saline |
|
10 |
18 |
14 |
|
|
Cubukcu 2004 |
5‐13 wk |
E: Hylan G‐F 20 |
WOMAC pain (5‐25) |
20 |
16 |
9 |
|
|
|
|
C: Saline |
|
10 |
18 |
15 |
|
|
Cubukcu 2004 |
1‐4 wk |
E: Hylan G‐F 20 |
WOMAC function (17‐85) |
20 |
50 |
41 |
|
|
|
|
C: Saline |
|
10 |
48 |
47 |
|
|
Cubukcu 2004 |
5‐13 wk |
E: Hylan G‐F 20 |
WOMAC function (17‐85) |
20 |
50 |
36 |
|
|
|
|
C: Saline |
|
10 |
48 |
47 |
|
|